Teleflex INC 8-K filings

Teleflex Incorporated announced an accelerated share repurchase program to buy back $250 million of its common stock, funded by proceeds from a recent business divestiture.

Teleflex announced its second quarter 2026 financial results, highlighting strong performance in Vascular and Surgical businesses, but revised revenue outlook due to integration delays in the Vascular Intervention business.

Teleflex Incorporated has filed an amendment to its Form 8-K to include unaudited pro forma financial information following the completion of its OEM business divestiture.

Teleflex Incorporated has successfully issued $500 million in 5.875% senior notes due 2032 to support its capital structure.

Teleflex Incorporated has awarded a $600,000 restricted stock unit grant to Interim CEO Stuart A. Randle for his extended service and leadership contributions.

Teleflex Incorporated is launching a private offering of $500 million in Senior Notes due 2032 to redeem its outstanding 4.625% Senior Notes due 2027.

Teleflex Incorporated has entered into a new $2.2 billion credit agreement to refinance its existing debt and provide ongoing liquidity.

Teleflex Incorporated announced the results of its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Teleflex Incorporated announced its first-quarter 2026 financial results, reporting revenue growth and maintaining its full-year financial outlook.

Teleflex Incorporated has named former Medtronic executive Jason Weidman as its new President and CEO, effective June 8, 2026.

Teleflex Incorporated responded to Irenic Capital Management's call for a sale, reaffirming its strategy to maximize shareholder value through ongoing divestitures, share repurchases, and debt reduction.

Teleflex Incorporated announced that the HSR waiting period for its OEM divestiture has expired, while its Acute Care and Interventional Urology divestiture received a Second Request from the FTC, extending its review.

Teleflex Incorporated announced robust 2025 financial results, provided 2026 guidance, and detailed a multi-year restructuring plan to optimize its portfolio following strategic divestitures.

Teleflex Incorporated announced the departure of President and CEO Liam J. Kelly, who also resigned from the Board, and detailed his separation agreement.

Teleflex Incorporated announced a leadership transition with an interim CEO appointment and a reduction in its preliminary full year 2025 revenue guidance.

Teleflex Incorporated announced the sale of its Acute Care, Interventional Urology, and OEM businesses for a combined $2.03 billion in cash, alongside a new $1 billion share repurchase program.

Teleflex Incorporated reported a significant GAAP loss in Q3 2025 due to substantial impairment charges, while adjusted EPS exceeded expectations despite a lowered full-year revenue guidance.

Teleflex Incorporated reported solid second-quarter financial results, exceeding revenue guidance, and significantly raised its full-year 2025 outlook, primarily driven by the recent acquisition of BIOTRONIK's Vascular Intervention business.

Teleflex Incorporated has amended its credit agreement to increase its delayed draw term loan commitments by $200 million, bringing the total facility to $700 million, specifically to fund the acquisition of MS Holding II SE's Vascular Intervention business.

Teleflex Incorporated amended its bylaws on May 9, 2025, primarily to remove the prohibition on stockholders taking action by written consent, alongside other routine corporate governance matters addressed at the annual meeting.

Teleflex announces its first quarter 2025 financial results, highlighting revenue and EPS figures while adjusting full-year guidance due to the impact of tariffs and strategic separation activities.

Teleflex Incorporated has entered into an accelerated share repurchase program (ASR) with JPMorgan Chase Bank to repurchase $300 million of its common stock.

Teleflex unveils plans to acquire BIOTRONIK's Vascular Intervention business and spin off Urology, Acute Care, and OEM segments into a separate publicly traded company.

Teleflex announced its third-quarter financial results, showing revenue growth but also a reduction in full-year revenue guidance, while raising the low end of its adjusted EPS guidance.

Teleflex's Executive Vice President and CFO, Thomas E. Powell, has established a stock trading plan to sell up to 53,754 shares of the company's common stock for financial planning purposes.

Teleflex has entered into an accelerated share repurchase agreement to buy back $200 million of its common stock.

Teleflex reported a 2.7% increase in adjusted revenue and a 0.3% increase in adjusted EPS for the second quarter of 2024, alongside a $500 million share repurchase authorization.

Teleflex Incorporated has disclosed modifications to executive compensation, the results of its annual stockholder meeting, and a stock trading plan for its CEO.

Teleflex announced its first quarter 2024 financial results, showing revenue growth and adjusted EPS increase, while updating its full-year guidance.

Teleflex reported a slight revenue increase for Q4 2023, but a decrease in adjusted EPS, while providing a positive outlook for 2024 revenue and adjusted EPS growth.